基于决策树模型的坤泰胶囊治疗更年期综合征的药物经济学评价OA

Objective To assess the cost-effectiveness of KunTai capsules in treating menopausal syndrome(MS).Methods Meta analysis of Kuntai capsule in MS treatment was searched in Chinese and English databases such as Chinese journal full-text database,Wanfang Data Knowledge Service Platform,International Health Technology Evaluation Agency Network(INAHTA)and EMBASE,and an economic evaluation model of Kuntai capsule in MS treatment was constructed from the perspective of health system to evaluate the economy of Kuntai capsule.Results In this paper,a meta-analysis is included and Treeage Pro software is used to construct a decision tree model.The results show that:The cost and health outcomes of Kuntai capsule combined with hormone therapy for MS 90 d were higher than those of hormone therapy alone,and the incremental cost-effectiveness ratio(ICER)was 170.65 yuan,that is,compared with hormone therapy alone,it cost 170.65 yuan more to improve Kupperman by using Kuntai capsule for each additional 1 minute.Assuming a patient's WTP threshold of 2022 per capita disposable income,Kuntai capsule combined with hormone regimens is more economical than hormone regimens alone.The results of sensitivity analysis show that the results of basic analysis are robust.Conclusion KunTai capsules combined with hormone therapy is more cost-effective than hormone therapy alone in terms of Kupperman symptom score.